Toggle Main Menu Toggle Search

Open Access padlockePrints

Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'-a new blood biomarker?

Lookup NU author(s): Professor Johannes Attems


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Simple, non-invasive tests for an early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers (plasma/serum, platelets, urine, connective tissue) for the early diagnosis of Alzheimer disease (AD) are available. In disease stages with evident cognitive disturbances, the clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. Diagnostic sensitivity and specificity even in early disease stages are improved by CSF markers, in particular combined tau and amyloid beta peptides (Abeta) and plasma markers (eg, Abeta-42/Abeta-40 ratio). Recently, a novel gene/protein--ALZAS (Alzheimer Associated Protein)--with a 79 amino acid sequence, containing the amyloid beta-42 fragment (Abeta-42), the amyloid precursor protein (APP) transmembrane signal and a 12 amino acid C-terminal, not present in any other known APP alleles, has been discovered on chromosome 21 within the APP region. Reverse transcriptase-PCR revealed the expression of the transcript of this protein in the cortex and hippocampal regions as well as in lymphocytes of human AD patients. The expression of ALZAS is mirrored by a specific autoimmune response in AD patients, directed against the ct-12 end of the ALZAS-peptide but not against the Abeta-sequence. ELISA studies of plasma detected highest titers of ALZAS in patients with mild cognitive impairment (presymptomatic AD), but only moderately increased titers in autopsy-confirmed AD, whereas low or undetectable ct-12 titers were found in cognitively intact age-matched subjects and young controls. The antigen, ALZAS protein, was detected in plasma in later clinical stages of AD. It is suggested that ALZAS represents an indicator in a dynamic equilibrium between both peripheral and brain degenerative changes in AD and may become a useful "non-invasive" diagnostic marker via a simple blood test.

Publication metadata

Author(s): Jellinger KA, Janetzky B, Attems J, Kienzl E

Publication type: Article

Publication status: Published

Journal: Journal of Cellular and Molecular Medicine

Year: 2008

Volume: 12

Issue: 4

Pages: 1094-1117

ISSN (print): 1582-1838

ISSN (electronic): 1582-4934

Publisher: Wiley-Blackwell Publishing Ltd.


DOI: 10.1111/j.1582-4934.2008.00313.x

Notes: Jellinger, Kurt A Janetzky, Bernd Attems, Johannes Kienzl, Elisabeth Research Support, Non-U.S. Gov't Review Romania Journal of cellular and molecular medicine J Cell Mol Med. 2008 Aug;12(4):1094-117. Epub 2008 Mar 19.


Altmetrics provided by Altmetric